Resend - Pfizer raises its 2026 performance outlook due to strong demand for its anticoagulant drug Eliquis

Correction: Location of release

Reuters, November 3 - Pfizer (PFE.N) on Tuesday raised its annual profit and revenue forecasts, driven by strong demand for its anticoagulant drug Eliquis.

The U.S. pharmaceutical company now expects annual sales to reach $62 billion to $64 billion, up from its previous forecast of $60.5 billion to $62.5 billion. The company also expects adjusted earnings per share this year of $2.95 to $3.05, compared to the earlier guidance of $2.80 to $3.00 per share.

Analysts had previously expected the company’s 2026 earnings per share to average $2.96, with full-year revenue of $62.17 billion.

(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may be inaccurate or lack required context, Reuters does not guarantee the accuracy of the automated translation, which is offered for reader convenience only. Reuters accepts no responsibility for any damage or loss caused by using the automated translation feature.)